New curcumin study a mile marker but not the destination

Alzheimer's, cardiovascular, and other chronic diseases; biomarkers, lifestyle, supplements, drugs, and health care.
circular
Senior Contributor
Senior Contributor
Posts: 5072
Joined: Sun Nov 03, 2013 10:43 am

New curcumin study a mile marker but not the destination

Postby circular » Sun May 29, 2016 10:57 pm

96 'older adults', 12-month, randomised, placebo-controlled, double-blind

'Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults.'

A significant time×treatment group interaction was observed for the Montreal Cognitive Assessment (repeated-measures analysis; time×treatment; F=3·85, P<0·05). Subsequent analysis revealed that this association was driven by a decline in function of the placebo group at 6 months that was not observed in the curcumin treatment group. No differences were observed between the groups for all other clinical and cognitive measures. Our findings suggest that further longitudinal assessment is required to investigate changes in cognitive outcome measures, ideally in conjunction with biological markers of neurodegeneration.
ApoE 3/4 > Thanks in advance for any responses made to my posts.

User avatar
RichardS
Contributor
Contributor
Posts: 246
Joined: Thu Nov 27, 2014 7:47 am

Re: New curcumin study a mile marker but not the destination

Postby RichardS » Wed Jun 01, 2016 5:40 pm

Some caution on this study.

There were significant baseline differences between the placebo and curcumin groups.
No differences between the treatment and placebo groups were observed in terms of the demographic and medical history variables evaluated (Table 1). Nevertheless, the placebo group performed significantly better at baseline in the digit symbol task (t=2·98, P<0·01), the MoCA (t=2·10, P<0·05) and cognitive composite (non-computerised) scores (t=2·40, P<0·05)...


The time×treatment variable was significant for the MoCA score (time×treatment; F=3·85, P<0·05; Table 3 and Fig. 2); however, it is important to note that the time variable itself was not significant (F=1·64, P=0·20). Mean MoCA scores improved by 0·64 points in the curcumin group and by 0·09 points in the placebo group from baseline to 12 months (Table 3 and Fig. 2). To assess whether the significant interaction observed in the repeated-measures analysis was driven by the decreased performance of the placebo group at the 6-month follow-up (a result not consistent with the 12-month follow-up assessment; Table 3 and Fig. 2), the analysis was re-run excluding the 6-month MoCA scores for both treatment groups. Using baseline and 12-month MoCA performance only, no significant interaction between time and treatment groups was observed (F=1·36, P=0·25; Table 3). No other differences in cognitive test performance were observed across the treatment groups.


It looks like the higher performance of the placebo group than curcumin at baseline led to a time x treatment interaction that really does not mean what we want it to mean from a therapeutic perspective.

circular
Senior Contributor
Senior Contributor
Posts: 5072
Joined: Sun Nov 03, 2013 10:43 am

Re: New curcumin study a mile marker but not the destination

Postby circular » Wed Jun 01, 2016 8:21 pm

Thank you Richard!
ApoE 3/4 > Thanks in advance for any responses made to my posts.

Surfrank57
Senior Contributor
Senior Contributor
Posts: 75
Joined: Sun Dec 27, 2015 4:17 pm

Re: New curcumin study a mile marker but not the destination

Postby Surfrank57 » Thu Jun 02, 2016 2:31 pm

Great find Richard...Thanks for scutinizing.
Frank


Return to “Prevention and Treatment”

Who is online

Users browsing this forum: No registered users and 11 guests